Sign in
CompletedNo phase

Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis.

Key facts

Who runs it
Changhai Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
220 people enrolled
Started
12 Mar 2025
Ended
20 Oct 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • time interval between ESWL and ERCP is 12h
  • time interval between ESWL and ERCP is greater than 12h
  • morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics)
Record updated
19 November 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • symptomatic adult patients diagnosed with chronic pancreatitis and main pancreatic duct positive stones(>5mm in diameter)
  • no ERCP and ESWL history before the admission
  • provides informed consent

Who cannot take part

  • suspected to have malignant tumors
  • history of pancreatic surgery or gastrojejunostomy (Billroth II)
  • with end-stage disease
  • with contraindications to ESWL or ERCP, such as pregnancy, abdominal aortic aneurysm, etc
  • acute pancreatitis within 3 days
  • pancreatic ascites

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to determine the optimal timing of endoscopic intervention after extracorporeal shock wave lithotripsy(ESWL) of chronic pancreatitis with pancreatic stones.

The 2 groups in the trial

  • Endoscopic group <12hTreatment being tested

    The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). After the last ESWL session, the patients are treated with following ERCP within 12h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary.

    Treatment: time interval between ESWL and ERCP is 12h and morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics)

  • Endoscopic group ≥12 hExisting treatment, for comparison

    The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). The time scale between the last ESWL session and following ERCP is greater than 12h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary.

    Treatment: time interval between ESWL and ERCP is greater than 12h and morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Optimal Timing of Endoscopic Intervention After Extracorporeal Shock-Wave Lithotripsy in the Treatment of Chronic Pancreatitis With Pancreatic Stones.
Record updated
19 November 2025